Loading stock data…
IART
$10.95+0.41 (+3.89%)
After Hours$10.54-0.41 (-3.74%)· Last close May 1
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Integra LifeSciences Holdings Corporation in the Healthcare sector is trading at $10.95. The stock is currently 36% below its 52-week high of $17.04, remaining 11.8% below its 200-day moving average. Technical signals show neutral RSI of 58 and bullish MACD crossover, explaining why IART maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 58) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.95
Potential Upside
5%
Whystock Fair Value$11.50
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Hold
Mean target$16.00+46.1%
Range$9.00 – $25.00
Fundamentals
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Sur...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$804.31M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.06
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.98%
Volume
Today's trading volume
816,959
Recent News
1 Value Stock to Research Further and 2 We Turn Down
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
Integra LifeSciences (IART) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Integra (IART) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is This the Right Time to Hold IART Stock in Your Portfolio?
Integra shows growth promise from strong CSS demand and global expansion, but debt load and macro pressures raise concerns for investors.
AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of -41.67% and +4.70%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
3 Cash-Burning Stocks That Concern Us
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.